APLS — курсы расширенных реанимационных мероприятий в педиатрии, спонсируемые Американской академией педиатрии и Американской коллегией врачей неотложной помощи (Advanced Pediatric Life Support)
AVPU — шкала для оценки уровня сознания («в ясном сознании»; «реакция на вербальные раздражители»; «реакция на боль»; «без сознания») (alert, verbal, pain, unresponsive)
CADASIL — церебральная аутосомно-доминантная артериопатия с подкорковыми инфарктами и лейкоэнцефалопатией (cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy)
DSM — Диагностическое и статистическое руководство по психическим расстройствам (Diagnostic and Statistical Manual of Mental Disorders)
EAST syndrome — эпилепсия, атаксия, сенсоневральная тугоухость и тубулопатия (epilepsy, ataxia, sensorineural hearing loss, and tubulopath)
EBM — доказательная медицина (evidance based medicine)
EPCAM — молекула адгезии эпителиальных клеток (epithelial cell adhesion molecule)
ESC — Европейское общество кардиологии (European Society of Cardiology)
EXIT — лечение плода вне матки во время родов (ех utero intrapartum treatment)
FcRs — Fc-рецепторы — белок, расположенный на поверхности нескольких видов клеток иммунной системы (естественных киллеров, макрофагов, нейтрофилов и тучных клеток) FDA — Комитет по контролю за лекарственными веществами и пищевыми добавками, США (Food and Drug Administration)
MELAS — митохондриальная энцефалопатия, лактоацидоз и инсультоподобные эпизоды (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes)
MELD — модель для оценки терминальной стадии заболеваний печени, предназначена для оценки относительной тяжести заболевания и прогноза жизни у пациентов с терминальной стадией печеночной недостаточности (ожидающих трансплантации печени) (model for end-stage liver disease)
MERRF — миоклоническая эпилепсия с рваными красными волокнами (myoclonic epilepsy with ragged red fibers)
MHC — главный комплекс гистосовместимости (major histocompatibility complex)
Mr — кажущаяся молекулярная масса
MRP — белок с множественной лекарственной устойчивостью (multidrug-resistant protein)
mTOR — мишень рапамицина у млекопитающих (mammalian target of rapamycin)
NB! — важно, обратить внимание (nota bene)
NICE — Национальный институт здоровья и клинического совершенствования (качества медицинской помощи) Великобритании (National Institute for Health and Clinical Excellence)
NK — естественные клетки-киллеры (natural killer) NMDA — И-метил-В-аспартат (N-methyl-D-aspartate)
NNT — число больных, которых необходимо пролечить, чтобы достичь какого-то указанного эффекта (number need to treatment)
OR — отношение шансов (odds ratio)
paCO2 — парциальное давление углекислого газа в артериальной крови
PALS — курсы расширенных реанимационных мероприятий в педиатрии (Pediatric Advanced Life Support)
PANDAS — аутоиммунное нейропсихиатрическое расстройство в детском возрасте, ассоциированное со стрептококковой инфекцией (pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection)
PANS — острый нейропсихиатрический синдром в детском возрасте (pediatric acute-onset neuropsychiatric syndrome)
paO2 — парциальное давление кислорода в артериальной крови
PAS — фуксинсернистая кислота, реактив Шиффа (periodic acid-Shiff)
PC — после еды (при назначениях) (post cibum) рСО2 — парциальное давление углекислого газа
PCSK-9 — пропротеиновая конвертаза субтилизинкексинового типа 9 (proprotein convertase subtilisin/kexin type 9)
PFAPA — периодическая лихорадка с афтозным стоматитом, фарингитом и лимфаденитом (periodic fevers with aphthous stomatitis, pharyngitis and adenitis)
PIM — показатель летального исхода у детей (pediatric index of mortality)
piO2 — парциальное давление кислорода во вдыхаемом воздухе
рО2 — парциальное давление кислорода
POLG — субъединица ДНК-полимеразы γ
PRISA II — оценка риска госпитализации у детей II (pediatric risk of admission)
PRISM — риск летального исхода у детей (pediatric risk of mortality)
PRN — при (по) необходимости (pro re nata — при возникновении обстоятельств)
PRSS — ген сериновой протеазы
PS — примечание (post scriptum)
PUVA-терапия — псорален-ультрафиолет А-терапия (psoralen and ultraviolet А)
Q#H — каждые # часов (при назначениях) (quaque... hora)
QAM — каждое утро (при назначениях) (quaque ante meridiem)
QPM — каждый вечер (при назначениях) (quaque post meridiem)
RAG — ген, активирующий рекомбиназу
RePEAT — пересмотренный инструмент для оценки педиатрической неотложной медицинской помощи (Revised Pediatric Emergency Assessment Tool)
RF — ревматоидный фактор
Rh — резус(-фактор)
Rh«-» — резус-отрицательн(ый)
Rh«+» — резус-положительн(ый)
ROHHAD — быстро развивающееся ожирение с дисфункцией гипоталамуса, гиповентиляцией и спонтанной дисрегуляцией (rapid-onset obesity with hypothalamic dysfunction, hypoventilation and autonomic dysregulation)
αDG-RD — дистрофии, связанные с α-дистрогликанами (alpha dystroglycan-related dystrophies)
β-ХГЧ — β-субъединица хорионического гонадотропина человека
В ходе подготовки статей по охране женского здоровья в терапии для пользователей сайта МедУнивер использованы труды следующих авторов:
Marjoribanks J, Farquhar C, Roberts H, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017; 1: CD004143.
Kovalchik SA, Tammemagi M, Berg CD, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med. 2013; 369: 245–254.
Pinsky PF, Yu K, Kramer BS, et al. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15 years follow-up. Gynecol Oncol. 2016; 143: 270–275.
Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016; 387: 945–956.
Arbyn M, Xu L, Simoens C, et al. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018; 5: CD009069.
Phelan S, Hagobian T, Brannen A, et al. Effect of an internet-based program on weight loss for low-income postpartum women: a randomized clinical trial. JAMA. 2017; 317: 2381–2391.
Chester RC, Kling JM, Manson JE. What the Women’s Health Initiative has taught us about menopausal hormone therapy. Clin Cardiol. 2018; 41: 247–252.
Wada H, Miyauchi K, Daida H. Gender differences in the clinical features and outcomes of patients with coronary artery disease. Expert Rev Cardiovasc Ther. 2019; 17: 127–133.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2018. [Epub ahead of print.]
Legato MJ, Johnson PA, Manson JE. Consideration of sex differences in medicine to improve health care and patient outcomes. JAMA. 2016; 316: 1865–1866.
Rosen SE, Henry S, Bond R, et al. Sex-specific disparities in risk factors for coronary heart disease. Curr Atheroscler Rep. 2015; 17: 1–11.
Myers ER, Moorman P, Gierisch JM, et al. Benefits and harms of breast cancer screening: a systematic review. JAMA. 2015; 314: 1615–1634.
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017; 317: 2402–2416.
US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, et al. Screening for gynecologic conditions with pelvic examination: US Preventive Services Task Force recommendation statement. JAMA. 2017; 317: 947–953.
Curry SJ, Krist AH, Owens DK, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018; 320: 674–686.
FRAX WHO Risk Assessment Tool. http://www.shef.ac.uk/FRAX/. Accessed March 13, 2019.
Stewart DE, Vigod S. Postpartum depression. N Engl J Med. 2016; 375: 2177–2186.
Kiang MV, Basu S, Chen J, et al. Assessment of changes in the geographical distribution of opioid-related mortality across the United States by opioid type, 1999–2016. JAMA Netw Open. 2019; 2: 1–10.
Chisolm MS, Payne JL. Management of psychotropic drugs during pregnancy. BMJ. 2016; 532: 1–15.
O’Connor E, Rossom RC, Henninger M, et al. Primary care screening for and treatment of depression in pregnant and postpartum women: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016; 315: 388–406.
Edelman A, Micks E, Gallo MF, et al. Continuous or extended cycle vs. cyclic use of combined hormonal contraceptives for contraception. Cochrane Database Syst Rev. 2014; 7: CD004695.
Piaggio G, Kapp N, von Hertzen H. Effect on pregnancy rates of the delay in the administration of levonorgestrel for emergency contraception: a combined analysis of four WHO trails. Contraception. 2011; 84: 35–39.
Shen J, Che Y, Showell E, et al. Interventions for emergency contraception. Cochrane Database Syst Rev. 2019; 1: CD001324.
Hohmann HL, Reeves MF, Chen BA, et al. Immediate versus delayed insertion of the levonorgestrel-releasing intrauterine device following dilation and evacuation: a randomized controlled trial. Contraception. 2012; 85: 240–245.
Black A, Guilbert E, Costescu D, et al. Canadian contraception consensus (part 2 of 4). J Obstet Gynaecol Can. 2015; 37: 1033–1039.
Tracy EE. Contraception: menarche to menopause. Obstet Gynecol Clin North Am. 2017; 44: 143–158.
Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008-2011. N Engl J Med. 2016; 374: 843–852.
Fact sheet. Unintended pregnancy in the United States. Guttmacher Inst. 2016; https://www.guttmacher.org/fact-sheet/unintended-pregnancy-united-states#1. Accessed April 22, 2019.
Daniels K, Daugherty J, Jones J, et al. Current contraceptive use and variation by selected characteristics among women aged 15–44: United States, 2011–2013. Natl Health Stat Report. 2015; 85: 1–14.
Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016; 65 (RR-3): 1–104.
Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep. 2016; 65 (RR-4): 1–66.
Practice Committee of the American Society for Reproductive Medicine. Combined hormonal contraception and the risk of venous thromboembolism: a guideline. Fertil Steril. 2017; 107: 43–51.
Dragoman MV, Tepper NK, Fu R, et al. A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception. Int J Gynaecol Obstet. 2018; 141: 287–294.
Morch LS, Skovlund CW, Hannaford PC, et al. Contemporary hormonal contraception and the risk of breast cancer. N Engl J Med. 2017; 377: 2228–2239.
Barriga P, Vanhauwaert P, Porcile A. Hormonal contraception and risk of breast cancer: a critical look. Gynecol Endocrinol. 2019: 1–3.
Iversen L, Sivasubramaniam S, Lee AJ, et al. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners’ Oral Contraception Study. Am J Obstet Gynecol. 2017; 216: 580.e1–580.e9.
ACOG practice bulletin no. 206 summary: use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2019; 133: 396–399.
Raymond EG, Cleland K. Clinical practice. Emergency contraception. N Engl J Med. 2015; 372: 1342–1348.
American College of Obstetricians and Gynecologists. Practice bulletin no. 152: emergency contraception. Obstet Gynecol. 2015; 126: e1–e11.
Curtis KM, Peipert JF. Long-acting reversible contraception. N Engl J Med. 2017; 376: 461–468.
Ho PC. Development of medical termination of pregnancy: a review. BJOG. 2017; 124: 1942–1947.
Magee LA, von Dadelszen P, Rey E, et al. Less-tight versus tight control of hypertension in pregnancy. N Engl J Med. 2015; 372: 407–417.
Churchill D, Duley L, Thornton JG, et al. Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks’ gestation. Cochrane Database Syst Rev. 2018; 10: CD003106.
Roberts JM, Myatt L, Spong CY, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med. 2010; 362: 1282–1291.
Rolnik DL, Wright D, Poon LC, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017; 377: 613–622.
Henderson JT, Whitlock EP, O’Connor E, et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014; 160: 695–703.
Skeith L, Carrier M, Kaaja R, et al. A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia. Blood. 2016; 127: 1650–1655.
Rodger MA, Hague WM, Kingdom J, et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet. 2014; 384: 1673–1683.
Bain E, Pierides KL, Clifton VL, et al. Interventions for managing asthma in pregnancy. Cochrane Database Syst Rev. 2014; 10: CD010660.
Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017; 390: 2347–2359.
Moore LE, Clokey D, Rappaport VJ, et al. Metformin compared with glyburide in gestational diabetes: a randomized controlled trial. Obstet Gynecol. 2010; 115: 55–59.
ACOG practice bulletin no. 202 summary: gestational hypertension and preeclampsia. Obstet Gynecol. 2019; 133: 211–214.
Garg AX, Nevis IF, McArthur E, et al. Gestational hypertension and preeclampsia in living kidney donors. N Engl J Med. 2015; 372: 124–133.
Reidy KJ, Hjorten RC, Simpson CL, et al. Fetal-not maternal-APOL1 genotype associated with risk for preeclampsia in those with African ancestry. Am J Hum Genet. 2018; 103: 367–376.
Vaught AJ, Kovell LC, Szymanski LM, et al. Acute cardiac effects of severe pre-eclampsia. J Am Coll Cardiol. 2018; 72: 1–11.
Zeisler H, Llurba E, Chantraine F, et al. Predictive value of the sFlt-1:plGF ratio in women with suspected preeclampsia. N Engl J Med. 2016; 374: 13–22.
Mol BW, Roberts CT, Thangaratinam S, et al. Pre-eclampsia. Lancet. 2016; 387: 999–1011.
Sedhai YR, Golamari R, Salei A, et al. May-Thurner syndrome. Am J Med Sci. 2018; 355: 510–514.
van der Pol LM, Tromeur C, Bistervels IM, et al. Pregnancy-adapted YEARS algorithm for diagnosis of suspected pulmonary embolism. N Engl J Med. 2019; 380: 1139–1149.
Linnemann B, Scholz U, Rott H, et al. Treatment of pregnancy-associated venous thromboembolism — position paper from the Working Group in Women’s Health of the Society of Thrombosis and Haemostasis (GTH). Vasa. 2016; 45: 103–118.
Murphy VE, Jensen ME, Gibson PG. Asthma during pregnancy: exacerbations, management, and health outcomes for mother and infant. Semin Respir Crit Care Med. 2017; 38: 160–173.
Mukerji G, Feig DS. Pharmacological management of gestational diabetes mellitus. Drugs. 2017; 77: 1723–1732.
Westbrook RH, Dusheiko G, Williamson C. Pregnancy and liver disease. J Hepatol. 2016; 64: 933–945.
Chlebowski RT, Rohan TE, Manson JE, et al. Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women’s Health Initiative randomized clinical trials. JAMA Oncol. 2015; 1: 296–305.
Cherry N, McNamee R, Heagerty A, et al. Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial. BJOG. 2014; 121: 700–705.
Gartlehner G, Patel SV, Feltner C, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2017; 318: 2234–2249.
Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017; 318: 927–938.
Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med. 2014; 161: 249–260.
Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016; 374: 1221–1231.
Archer DF, Kimble TD, Lin FDY, et al. A randomized, multicenter, double-blind, study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with vaginal dryness as the most bothersome symptom. J Womens Health (Larchmt). 2018; 27: 231–237.
Kroll R, Archer DF, Lin Y, et al. A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom. Menopause. 2018; 25: 133–138.
Ayers B, Smith M, Hellier J, et al. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause. 2012; 19: 749–759.
Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol. 2012; 13: 309–318.
Ee C, Xue C, Chondros P, et al. Acupuncture for menopausal hot flashes: a randomized trial. Ann Intern Med. 2016; 164: 146–154.
McCurry SM, Guthrie KA, Morin CM, et al. Telephone-based cognitive behavioral therapy for insomnia in perimenopausal and postmenopausal women with vasomotor symptoms: a MsFLASH randomized clinical trial. JAMA Intern Med. 2016; 176: 913–920.
Davari-Tanha F, Soleymani-Farsani M, Asadi M, et al. Comparison of citalopram and venlafaxine’s role in treating sleep disturbances in menopausal women, a randomized, double-blind, placebo-controlled trial. Arch Gynecol Obstet. 2016; 293: 1007–1013.
Paramsothy P, Harlow SD, Nan B, et al. Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women’s Health Across the Nation. Menopause. 2017; 24: 142–149.
Santoro N, Crawford SL, El Khoudary SR, et al. Menstrual cycle hormone changes in women traversing the menopause: study of women’s health across the nation. J Clin Endocrinol Metab. 2017; 102: 2218–2229.
Marin R, Diaz M. Estrogen interactions with lipid rafts related to neuroprotection. Impact of brain ageing and menopause. Front Neurosci. 2018; 12: 1–18.
Schmidt PJ, Ben Dor R, Martinez PE, et al. Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry. 2015; 72: 714–726.
Gleason CE, Dowling NM, Wharton W, et al. Effects of hormone therapy on cognition and mood in recently postmenopausal women: findings from the randomized, controlled KEEPS-Cognitive and Affective Study. PLoS Med. 2015; 12: 1–25.
Gervais NJ, Mong JA, Lacreuse A. Ovarian hormones, sleep and cognition across the adult female lifespan: an integrated perspective. Front Neuroendocrinol. 2017; 47: 134–153.
Karlamangla AS, Burnett-Bowie SM, Crandall CJ. Bone health during the menopause transition and beyond. Obstet Gynecol Clin North Am. 2018; 45: 695–708.
Karvonen-Gutierrez C, Kim C. Association of mid-life changes in body size, body composition and obesity status with the menopausal transition. Healthcare (Basel). 2016; 4: 1–16.
Avis NE, Crawford SL, Greendale G, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015; 175: 531–539.
Reynolds EE, Bates C, Richardson M, et al. Should this patient receive hormone therapy for her menopausal symptoms? Grand rounds discussion from Beth Israel Deaconess Medical Center. Ann Intern Med. 2018; 168: 203–209.
Joffe H, Crawford SL, Freeman MP, et al. Independent contributions of nocturnal hot flashes and sleep disturbance to depression in estrogen-deprived women. J Clin Endocrinol Metab. 2016; 101: 3847–3855.
Grossman DC, Curry SJ, Owens DK, et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: US Preventive Services Task Force recommendation statement. JAMA. 2017; 318: 2224–2233.
The North American Menopause Society. The 2017 hormone therapy position statement of the North American Menopause Society. Menopause. 2018; 25: 1362–1387.
Donders GGG, Ruban K, Bellen G, et al. Pharmacotherapy for the treatment of vaginal atrophy. Expert Opin Pharmacother. 2019: 1–15.
Pitsouni E, Grigoriadis T, Falagas ME, et al. Laser therapy for the genitourinary syndrome of menopause. A systematic review and meta-analysis. Maturitas. 2017; 103: 78–88.
Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015; 22: 1155–1172, quiz 73-4.
Edwards D, Panay N. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition? Climacteric. 2016; 19: 151–161.
Feltner C, Wallace I, Berkman N, et al. Screening for intimate partner violence, elder abuse, and abuse of vulnerable adults: evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018; 320: 1688–1701.
Rivas C, Ramsay J, Sadowski L, et al. Advocacy interventions to reduce or eliminate violence and promote the physical and psychosocial well-being of women who experience intimate partner abuse. Cochrane Database Syst Rev. 2015; 12: CD005043.
Tirado-Mu?oz J, Gilchrist G, Farre M, et al. The efficacy of cognitive behavioural therapy and advocacy interventions for women who have experienced intimate partner violence: a systematic review and meta-analysis. Ann Med. 2014; 46: 567–586.
Arroyo K, Lundahl B, Butters R, et al. Short-term interventions for survivors of intimate partner violence: a systematic review and meta-analysis. Trauma Violence Abuse. 2017; 18: 155–171.
Nesset MB, Lara-Cabrera ML, Dalsbo TK, et al. Cognitive behavioural group therapy for male perpetrators of intimate partner violence: a systematic review. BMC Psychiatry. 2019; 19: 1–13.
Taft CT, Creech SK, Gallagher MW, et al. Strength at Home couples program to prevent military partner violence: a randomized controlled trial. J Consult Clin Psychol. 2016; 84: 935–945.
Zaher E, Keogh K, Ratnapalan S. Effect of domestic violence training: systematic review of randomized controlled trials. Can Fam Physician. 2014; 60: 618–624.
Sawyer S, Coles J, Williams A, et al. A systematic review of intimate partner violence educational interventions delivered to allied health care practitioners. Med Educ. 2016; 50: 1107–1121.
Fellmeth GL, Heffernan C, Nurse J, et al. Educational and skills-based interventions for preventing relationship and dating violence in adolescents and young adults. Cochrane Database Syst Rev. 2013; 6: CD004534.
Jahanfar S, Janssen PA, Howard LM, et al. Interventions for preventing or reducing domestic violence against pregnant women. Cochrane Database Syst Rev. 2013; 2: CD009414.
Kiely M, El-Mohandes AA, El-Khorazaty MN, et al. An integrated intervention to reduce intimate partner violence in pregnancy: a randomized controlled trial. Obstet Gynecol. 2010; 115: 273–283.
Hegarty K, O’Doherty L, Taft A, et al. Screening and counselling in the primary care setting for women who have experienced intimate partner violence (WEAVE): a cluster randomised controlled trial. Lancet. 2013; 382: 249–258.
Feder G, Davies RA, Baird K, et al. Identification and Referral to Improve Safety (IRIS) of women experiencing domestic violence with a primary care training and support programme: a cluster randomised controlled trial. Lancet. 2011; 378: 1788–1795.
Miller E, McCaw B. Intimate partner violence. N Engl J Med. 2019; 380: 850–857.
Gehring KS, Vaske JC. Out in the open: the consequences of intimate partner violence for victims in same-sex and opposite-sex relationships. J Interpers Violence. 2017; 32: 3669–3692.
Rolla L, Giardina G, Caldarera AM, et al. When intimate partner violence meets same sex couples: a review of same sex intimate partner violence. Front Psychol. 2018; 9: 1–13.
Chmielowska M, Fuhr DC. Intimate partner violence and mental ill health among global populations of Indigenous women: a systematic review. Soc Psychiatry Psychiatr Epidemiol. 2017; 52: 689–704.
Velopulos CG, Carmichael H, Zakrison TL, et al. Comparison of male and female victims of intimate partner homicide and bidirectionality—an analysis of the National Violent Death Reporting System. J Trauma Acute Care Surg. 2019. [Epub ahead of print.]
Fulu E, Miedema S. Violence against women: globalizing the integrated ecological model. Violence Against Women. 2015; 21: 1431–1455.
Hester M, Ferrari G, Jones SK, et al. Occurrence and impact of negative behaviour, including domestic violence and abuse, in men attending UK primary care health clinics: a cross-sectional survey. BMJ Open. 2015; 5: 1–10.
Bacchus LJ, Buller AM, Ferrari G, et al. Occurrence and impact of domestic violence and abuse in gay and bisexual men: a cross sectional survey. Int J STD AIDS. 2017; 28: 16–27.
Reingle Gonzalez JM, Jetelina KK, Olague S, et al. Violence against women increases cancer diagnosis: result from a meta-analytic review. Prev Med. 2018; 114: 168–179.
O’Neill A, Scovelle AJ. Intimate partner violence perpetration and cardiovascular risk: a systematic review. Prev Med Rep. 2018; 31: 10–19.
Chisholm CA, Bullock L, Ferguson JEJ 2nd. Intimate partner violence and pregnancy: epidemiology and impact. Am J Obstet Gynecol. 2017; 217: 141–144.
Donovan BM, Spracklen CN, Schweizer ML, et al. Intimate partner violence during pregnancy and the risk for adverse infant outcomes: a systematic review and meta-analysis. BJOG. 2016; 123: 1289–1299.
Fry DA, Elliott SP. Understanding the linkages between violence against women and violence against children. Lancet Glob Health. 2017; 5: e472–e473.
Fulu E, Meidema S, Roselli T, et al. Pathways between childhood trauma, intimate partner violence, and harsh parenting: finding from the UN Multi-Country Study on Men and Violence in Asia and the Pacific. Lancet Glob Health. 2017; 5: e512–e522.
Curry SJ, Krist AH, Owens DK, et al. Screening for intimate partner violence, elder abuse, and abuse of vulnerable adults: US Preventive Services Task Force Final recommendation statement. JAMA. 2018; 320: 1678–1687.
Penti B, Timmons J, Adms D. The role of the physician when a patient discloses intimate partner violence perpetration: a literature review. J Am Board Fam Med. 2018; 31: 635–644.
World Health Organization. Responding to Intimate Partner Violence and Sexual Violence Against Women: WHO Clinical and Policy Guidelines. Женева: ВОЗ; 2013.
Труды отечественных авторов при подготовке статей по терапии для пользователей сайта - не использовались, так как их вы всегда можете найти в библиотеках.
